FIFARMA Introduction

CASSS LATAM Forum, Sep 5-6, Mexico City

Thomas Schreitmueller,
Co-chair FIFARMA Regulatory and Biologics WG
FIFARMA Yesterday and Today

**Creation 1962**
- Members: local associations
- Direction: rotated by local associations

**FIFARMA 2.0 Launched 2014**
- Regional focus, no longer “add on”
- New structure and goals
- Members: 9 local associations and 11 multi-national companies
Vision and Mission

Vision

• To be the regional voice of the innovative pharmaceutical industry, supporting the development of a sustainable and patient centric healthcare system in Latin America.

Mission

• To engage in the development of policies that foster the access to high quality pharmaceutical innovations that prolong, preserve and improve life for patients in Latin America.
FIFARMA Working Groups

**Health Technology Assessment (HTA)**
- HTAs relations with industry
- HTA committees in associations
- Position Paper
- MCDA
- Stakeholder & Education mapping
- **28 professionals**

**Regulatory and Biologics (R&B)**
- Biotherapeutic guidelines
- Policy & Communications
- Regulatory transparency
- Pharmacovigilance
- **27 professionals**

**Vaccines**
- Project to partner with PAHO
- PAHO stakeholder mapping
- Local associations survey
- PAHO Vaccines lots release workshop – October 2015
- **19 professionals**

**PAHO & Institutional Relations (PAHO & IR)**
- TI Compliance project with participation of IFPMA
- Strategic partnership with PAHO Foundation
- Coordination of other WG initiatives to be worked with PAHO
- **28 professionals**
The FIFARMA Session @ CASSS

**Public Quality Control Testing of Pharmaceutical Products**

- Session Co-Chairs: Gustavo Grampp, Amgen Inc. and Janett Mugaburu-Richards, Pfizer, Inc.

**Transparency of Regulatory Decision Making**

- Session Co-Chairs: Silvia Moscoso Salcedo and Maria Cristina Mota Pina, AbbVie, Inc.
Thank You